Anti-carbamylated protein antibodies are associated with early abatacept response in rheumatoid arthritis Comment on: Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept

We read the article by Kumar et al., which is the first to address the association between anti-carbamylated protein antibodies (anti-CarP) and the response to abatacept (ABA) in rheumatoid arthritis (RA), with great interest. The most striking findings were the better response (a significant reduct...

Descripción completa

Detalles Bibliográficos
Autores: Castellanos-Moreira, R., Gómez, A., Haro Villar, Isabel, Ruiz-Esquide, V., Marsal, V., Sanmartí, Raimon
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/251648
Acceso en línea:http://hdl.handle.net/10261/251648
Access Level:acceso abierto
Palabra clave:Anti-carbamylated protein antibodies
id ES_0fc2e64879fc8f04546e55e1e332c71b
oai_identifier_str oai:digital.csic.es:10261/251648
network_acronym_str ES
network_name_str España
repository_id_str
spelling Anti-carbamylated protein antibodies are associated with early abatacept response in rheumatoid arthritis Comment on: Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abataceptLetters to the editorsCastellanos-Moreira, R.Gómez, A.Haro Villar, IsabelRuiz-Esquide, V.Marsal, V.Sanmartí, RaimonAnti-carbamylated protein antibodiesWe read the article by Kumar et al., which is the first to address the association between anti-carbamylated protein antibodies (anti-CarP) and the response to abatacept (ABA) in rheumatoid arthritis (RA), with great interest. The most striking findings were the better response (a significant reduction in δ-DAS28-PCR) to ABA in anti-CarP positive patients and a reduction in anti-CarP levels. No differences in the therapeutic response were found when analyzed according to ACPA nor rheumatoid factor status (1).Peer reviewedClinical and Experimental RheumatologyConsejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]202120212021info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionhttp://hdl.handle.net/10261/251648reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)InglésSíinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/2516482026-05-22T06:33:51Z
dc.title.none.fl_str_mv Anti-carbamylated protein antibodies are associated with early abatacept response in rheumatoid arthritis Comment on: Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept
Letters to the editors
title Anti-carbamylated protein antibodies are associated with early abatacept response in rheumatoid arthritis Comment on: Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept
spellingShingle Anti-carbamylated protein antibodies are associated with early abatacept response in rheumatoid arthritis Comment on: Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept
Castellanos-Moreira, R.
Anti-carbamylated protein antibodies
title_short Anti-carbamylated protein antibodies are associated with early abatacept response in rheumatoid arthritis Comment on: Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept
title_full Anti-carbamylated protein antibodies are associated with early abatacept response in rheumatoid arthritis Comment on: Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept
title_fullStr Anti-carbamylated protein antibodies are associated with early abatacept response in rheumatoid arthritis Comment on: Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept
title_full_unstemmed Anti-carbamylated protein antibodies are associated with early abatacept response in rheumatoid arthritis Comment on: Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept
title_sort Anti-carbamylated protein antibodies are associated with early abatacept response in rheumatoid arthritis Comment on: Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept
dc.creator.none.fl_str_mv Castellanos-Moreira, R.
Gómez, A.
Haro Villar, Isabel
Ruiz-Esquide, V.
Marsal, V.
Sanmartí, Raimon
author Castellanos-Moreira, R.
author_facet Castellanos-Moreira, R.
Gómez, A.
Haro Villar, Isabel
Ruiz-Esquide, V.
Marsal, V.
Sanmartí, Raimon
author_role author
author2 Gómez, A.
Haro Villar, Isabel
Ruiz-Esquide, V.
Marsal, V.
Sanmartí, Raimon
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Anti-carbamylated protein antibodies
topic Anti-carbamylated protein antibodies
description We read the article by Kumar et al., which is the first to address the association between anti-carbamylated protein antibodies (anti-CarP) and the response to abatacept (ABA) in rheumatoid arthritis (RA), with great interest. The most striking findings were the better response (a significant reduction in δ-DAS28-PCR) to ABA in anti-CarP positive patients and a reduction in anti-CarP levels. No differences in the therapeutic response were found when analyzed according to ACPA nor rheumatoid factor status (1).
publishDate 2021
dc.date.none.fl_str_mv 2021
2021
2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/251648
url http://hdl.handle.net/10261/251648
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Clinical and Experimental Rheumatology
publisher.none.fl_str_mv Clinical and Experimental Rheumatology
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403472033480704
score 15,812429

Similares en LA Referencia